CrossrefInfokarte
Methodological concerns regarding "Clinical outcomes with vutrisiran in transthyretin amyloidosis: A systematic review and meta-analysis of randomized trials"
Global Cardiology Science and Practice · 2026-10-30 · 2026 (5)
DOI: 10.21542/gcsp.2026.44 ↗Abstract
[No abstract, showing first paragraph of letter] Dear Editor, We read with interest the meta-analysis by Ahmed et al. evaluating vutrisiran in transthyretin amyloidosis (ATTR) [1]. While the review addresses a clinically important question, we wish to raise several methodological concerns not addressed in the manuscript's limitations section.
EUVIMED